| 1 |
Yang H, Yao W, Yang J. Overview of the development of HBV small molecule inhibitors. Eur J Med Chem 2023;249:115128. [PMID: 36709647 DOI: 10.1016/j.ejmech.2023.115128] [Reference Citation Analysis]
|
| 2 |
Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K, Martin R, Aeschbacher T, Suri V, Tan SK, Feierbach B, Gaggar A, Marcellin P, Buti Ferret M, Janssen HLA, Gane E, Meagher N, Price DJ, Wong D, Thompson AT, Revill PA. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B. Aliment Pharmacol Ther 2023;57:509-23. [PMID: 36427857 DOI: 10.1111/apt.17299] [Reference Citation Analysis]
|
| 3 |
Bekheit MS, Panda SS, Girgis AS. Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2. European Journal of Medicinal Chemistry 2023. [DOI: 10.1016/j.ejmech.2023.115292] [Reference Citation Analysis]
|
| 4 |
Singh PK. Molecular modeling studies of fused pyrimidine derivatives at various receptors. Fused Pyrimidine-Based Drug Discovery 2023. [DOI: 10.1016/b978-0-443-18616-5.00010-7] [Reference Citation Analysis]
|
| 5 |
Knak T, Abdullaziz MA, Höfmann S, Alves Avelar LA, Klein S, Martin M, Fischer M, Tanaka N, Kurz T. Over 40 Years of Fosmidomycin Drug Research: A Comprehensive Review and Future Opportunities. Pharmaceuticals (Basel) 2022;15. [PMID: 36559004 DOI: 10.3390/ph15121553] [Reference Citation Analysis]
|
| 6 |
Han G, Zhou G, Sun T, Luo X, Xu J, Chen C, Xu W, Jiang S, Wang C. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study. J Matern Fetal Neonatal Med 2022;35:10551-8. [PMID: 36253882 DOI: 10.1080/14767058.2022.2134771] [Reference Citation Analysis]
|
| 7 |
Xu X, Chen Y, Lu X, Zhang W, Fang W, Yuan L, Wang X. An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges. Biochem Pharmacol 2022;205:115279. [PMID: 36209840 DOI: 10.1016/j.bcp.2022.115279] [Reference Citation Analysis]
|
| 8 |
Clercq E. Reflections on the Rega Institute for Medical Research, at the fiftieth anniversary of the Rega Stichting vzw (Rega Instituut vzw, Rega Foundation). Antivir Chem Chemother 2022;30:20402066221129979. [PMID: 36305032 DOI: 10.1177/20402066221129979] [Reference Citation Analysis]
|
| 9 |
Kayes T, Crane H, Symonds A, Dumond J, Cottrell M, Di Girolamo J, Manandhar S, Lim TH, Gane E, Kashuba A, Levy MT. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Aliment Pharmacol Ther 2022;56:510-8. [PMID: 35599363 DOI: 10.1111/apt.17040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Dave M, Sareen M, Goyal A, Gonchikar NT, Shah Y. Tenofovir-induced distal renal tubular acidosis: A rare cause of recurrent hypokalaemic paralysis. Journal of the Royal College of Physicians of Edinburgh. [DOI: 10.1177/14782715221103643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Krečmerová M, Majer P, Rais R, Slusher BS. Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects. Front Chem 2022;10:889737. [PMID: 35668826 DOI: 10.3389/fchem.2022.889737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Zhang H, Gao L, Lou J, Wu M, Chen H, Yang L, Liu J, Zhu X, Li X, Li C, Wang M, Liu C, Guo W, Wang Y, Gao Z, Han L, Wang D, Jin W, Ding Y. First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects. Front Pharmacol 2022;13:873588. [PMID: 35662718 DOI: 10.3389/fphar.2022.873588] [Reference Citation Analysis]
|
| 13 |
Nadeali Z, Mohammad-Rezaei F, Aria H, Nikpour P. Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19. Life Sci 2022;297:120482. [PMID: 35288174 DOI: 10.1016/j.lfs.2022.120482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Li G, Wang Y, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm Sin B 2022;12:1567-90. [PMID: 35847492 DOI: 10.1016/j.apsb.2021.11.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 15 |
De Jonghe S, Herdewijn P. An Overview of Marketed Nucleoside and Nucleotide Analogs. Curr Protoc 2022;2:e376. [PMID: 35263029 DOI: 10.1002/cpz1.376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Kim SH, Cho EJ, Jang BO, Lee K, Choi JK, Choi GH, Lee JH, Yu SJ, Kim YJ, Lee YB, Yoon JH, Kim JW, Jeong SH, Jang ES. Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver Int 2022;42:320-9. [PMID: 34679254 DOI: 10.1111/liv.15086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Chen R, Zou J, Long L, Huang H, Zhang M, Fan X, Huang Y. Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B. Front Med 2022;8:796901. [DOI: 10.3389/fmed.2021.796901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: Current therapeutics and emerging technologies. Front Immunol 2022;13:1059133. [PMID: 36389670 DOI: 10.3389/fimmu.2022.1059133] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Sherif DA, Makled MN, Suddek GM. The HIV reverse transcriptase Inhibitor Tenofovir suppressed DMH/HFD-induced colorectal cancer in Wistar rats. Fundam Clin Pharmacol 2021;35:940-54. [PMID: 33829539 DOI: 10.1111/fcp.12679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Kalčic F, Zgarbová M, Hodek J, Chalupský K, Dračínský M, Dvořáková A, Strmeň T, Šebestík J, Baszczyňski O, Weber J, Mertlíková-Kaiserová H, Janeba Z. Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties. J Med Chem 2021;64:16425-49. [PMID: 34713696 DOI: 10.1021/acs.jmedchem.1c01444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Bavaro DF, Laghetti P, Poliseno M, De Gennaro N, Di Gennaro F, Saracino A. A Step Closer to the "Fourth 90": A Practical Narrative Review of Diagnosis and Management of Nutritional Issues of People Living with HIV. Diagnostics (Basel) 2021;11:2047. [PMID: 34829394 DOI: 10.3390/diagnostics11112047] [Reference Citation Analysis]
|
| 22 |
Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 23 |
Brunet L, Mallon P, Fusco JS, Wohlfeiler MB, Prajapati G, Beyer A, Fusco GP. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization. Clin Drug Investig 2021;41:955-65. [PMID: 34546533 DOI: 10.1007/s40261-021-01081-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Cobb DA, Smith N, Deodhar S, Bade AN, Gautam N, Shetty BLD, McMillan J, Alnouti Y, Cohen SM, Gendelman HE, Edagwa B. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nat Commun 2021;12:5458. [PMID: 34531390 DOI: 10.1038/s41467-021-25690-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 25 |
Chandler CJ, Creasy SL, Adams BJ, Eaton LA, Bukowski LA, Egan JE, Friedman MR, Stall RD, Whitfield DL. Characterizing Biomedical HIV Prevention Awareness and Use Among Black Transgender Women in the United States. AIDS Behav 2021;25:2929-40. [PMID: 33606134 DOI: 10.1007/s10461-021-03189-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 26 |
Darnell J, Jain S, Sun X, Qin H, Reynolds T, Karris MY, Hill LA. Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen. Medicine (Baltimore) 2021;100:e27047. [PMID: 34449491 DOI: 10.1097/MD.0000000000027047] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 27 |
Zaongo SD, Liu Y, Harypursat V, Song F, Xia H, Ma P, Chen Y. P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target. Front Immunol 2021;12:710121. [PMID: 34434194 DOI: 10.3389/fimmu.2021.710121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 29 |
Li ZB, Li L, Niu XX, Chen SH, Fu YM, Wang CY, Liu Y, Shao Q, Chen G, Ji D. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int 2021;41:1254-64. [PMID: 33404182 DOI: 10.1111/liv.14786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 30 |
De Nicolò A, Manca A, Ianniello A, Palermiti A, Calcagno A, Ferrara M, Antonucci M, Cusato J, Avataneo V, De Vivo E, Bonora S, De Rosa FG, Di Perri G, D'Avolio A. Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. Pharmaceuticals (Basel) 2021;14:460. [PMID: 34068180 DOI: 10.3390/ph14050460] [Reference Citation Analysis]
|
| 31 |
Nocentini A, Capasso C, Supuran CT. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present). Expert Opin Ther Pat 2021;:1-10. [PMID: 33909515 DOI: 10.1080/13543776.2021.1923694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 32 |
Dietz J, Ferenc D, Jamison TF, Gupton BF, Opatz T. Di- tert -butyl Phosphonate Route to the Antiviral Drug Tenofovir. Org Process Res Dev 2021;25:789-98. [DOI: 10.1021/acs.oprd.0c00473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Okochi H, Louie A, Phung N, Zhang K, Tallerico RM, Kuncze K, Spinelli MA, Koss CA, Benet LZ, Gandhi M. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. Drug Test Anal 2021;13:1354-70. [PMID: 33742745 DOI: 10.1002/dta.3033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat 2021;31:325-37. [PMID: 33475441 DOI: 10.1080/13543776.2021.1880568] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 20.5] [Reference Citation Analysis]
|
| 35 |
Li G, Yue T, Zhang P, Gu W, Gao LJ, Tan L. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. Molecules 2021;26:923. [PMID: 33572409 DOI: 10.3390/molecules26040923] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 36 |
De La Garza R, Rodrigo H, Fernandez F, Roy U. The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley. Curr HIV Res 2019;17:377-87. [PMID: 31663481 DOI: 10.2174/1570162X17666191029162235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 37 |
Zeng QL, Yu ZJ, Ji F, Li GM, Zhang GF, Xu JH, Chen ZM, Cui GL, Li W, Zhang DW, Li J, Lv J, Li ZQ, Liang HX, Sun CY, Pan YJ, Liu YM, Wang FS. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clin Infect Dis 2021:ciaa1939. [PMID: 33395488 DOI: 10.1093/cid/ciaa1939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 38 |
Yu H, Yang H, Shi E, Tang W. Development and Clinical Application of Phosphorus-Containing Drugs. Med Drug Discov 2020;8:100063. [PMID: 32864606 DOI: 10.1016/j.medidd.2020.100063] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 39 |
Li M, Zhou L, Dorsey HG, Musoff C, Jnr DA, Schoen N, Djan K, Paintsil E. Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line. Antiviral Res 2020;183:104948. [PMID: 32980447 DOI: 10.1016/j.antiviral.2020.104948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 40 |
Huang BX, Liu Y, Fan ZP, Si LL, Chen RJ, Wang J, Luo D, Wang FS, Xu DP, Liu XG. Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. World J Gastroenterol 2020; 26(35): 5314-5327 [PMID: 32994690 DOI: 10.3748/wjg.v26.i35.5314] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 41 |
Alghamdi AS, Alothmani HS, Mogharbel M, Albiladi H, Babatin M. Clinical Characteristics of Hepatitis B Virus Patients After Switching to Tenofovir Alafenamide Fumarate: A Retrospective Observational Study. Cureus 2020. [DOI: 10.7759/cureus.10380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 42 |
Parsons TL, Gwenden KN, Marzinke MA. Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma. Antimicrob Agents Chemother 2020;64:e00930-20. [PMID: 32540983 DOI: 10.1128/AAC.00930-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J Proteome Res. 2020;19:4690-4697. [PMID: 32692185 DOI: 10.1021/acs.jproteome.0c00392] [Cited by in Crossref: 127] [Cited by in F6Publishing: 162] [Article Influence: 42.3] [Reference Citation Analysis]
|
| 44 |
Huang XS, Luo RH, Hu XL, Chen H, Xiang SY, Tang CR, Zhang CT, Shen XN, Zheng YT. The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. Curr HIV Res 2020;18:332-41. [PMID: 32562524 DOI: 10.2174/1570162X18666200620211922] [Reference Citation Analysis]
|
| 45 |
Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, Kim SG, Kim EJ, Casel MAB, Rollon R, Jang SG, Lee MH, Chang JH, Song MS, Jeong HW, Choi Y, Chen W, Shin WJ, Jung JU, Choi YK. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. mBio 2020;11:e01114-20. [PMID: 32444382 DOI: 10.1128/mBio.01114-20] [Cited by in Crossref: 114] [Cited by in F6Publishing: 129] [Article Influence: 38.0] [Reference Citation Analysis]
|
| 46 |
Drosu NC, Edelman ER, Housman DE. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc Natl Acad Sci U S A 2020;117:12368-74. [PMID: 32409608 DOI: 10.1073/pnas.2002392117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 47 |
Chen MB, Wang H, Zheng QH, Cui WY, Xu HL, Zheng XW. Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2020;99:e20160. [PMID: 32384507 DOI: 10.1097/MD.0000000000020160] [Reference Citation Analysis]
|
| 48 |
Vélez-Díaz-Pallarés M, Gramage-Caro T, Rodríguez-Sagrado MÁ, Montero-Llorente B, Bermejo-Vicedo T. Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine. Biomedica 2020;40:132-8. [PMID: 32463615 DOI: 10.7705/biomedica.4989] [Reference Citation Analysis]
|
| 49 |
Jiang Y, Gao X, Singh ON, Zhang W, Agrahari V, Peet MM, Clark MR, Doncel GF, Banga AK. Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats. Int J Pharm 2020;582:119342. [PMID: 32315746 DOI: 10.1016/j.ijpharm.2020.119342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 50 |
Lengauer H, Makuc D, Šterk D, Perdih F, Pichler A, Trdan Lušin T, Plavec J, Časar Z. Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates. Pharmaceutics 2020;12:E342. [PMID: 32290280 DOI: 10.3390/pharmaceutics12040342] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Premaor MO, Compston JE. People living with HIV and fracture risk. Osteoporos Int 2020;31:1633-44. [PMID: 32206852 DOI: 10.1007/s00198-020-05350-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 52 |
Chien M, Anderson TK, Jockusch S, Tao C, Kumar S, Li X, Russo JJ, Kirchdoerfer RN, Ju J. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase. bioRxiv. 2020;. [PMID: 32511320 DOI: 10.1101/2020.03.18.997585] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 53 |
Eke AC, Brooks KM, Gebreyohannes RD, Sheffield JS, Dooley KE, Mirochnick M. Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opin Drug Metab Toxicol 2020;16:333-42. [PMID: 32125906 DOI: 10.1080/17425255.2020.1738384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 54 |
Xiao D, Ling KHJ, Tarnowski T, Majeed SR, German P, Kearney BP, Zhao Y, Chen Y, Ma L, zhang T. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer. Analytical Biochemistry 2020;593:113611. [DOI: 10.1016/j.ab.2020.113611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 55 |
Yasutake Y, Hattori SI, Tamura N, Matsuda K, Kohgo S, Maeda K, Mitsuya H. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine. Sci Rep 2020;10:3021. [PMID: 32080249 DOI: 10.1038/s41598-020-59775-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 56 |
Liu Y, Liu H, Hu Z, Ding Y, Pan XB, Zou J, Xi J, Yu G, Huang H, Luo MT, Guo F, Liu S, Sheng Q, Jia J, Zheng YT, Wang J, Chen X, Guo JT, Wei L, Lu F. Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. Hepatology 2020;71:463-76. [PMID: 31278760 DOI: 10.1002/hep.30844] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 57 |
Straubinger T, Kay K, Bies R. Modeling HIV Pre-Exposure Prophylaxis. Front Pharmacol 2019;10:1514. [PMID: 32082142 DOI: 10.3389/fphar.2019.01514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 58 |
Maeda K, Das D, Kobayakawa T, Tamamura H, Takeuchi H. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. Curr Top Med Chem 2019;19:1621-49. [PMID: 31424371 DOI: 10.2174/1568026619666190712204603] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 59 |
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol 2019;34:2004-10. [PMID: 31017689 DOI: 10.1111/jgh.14686] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 60 |
Njenda DT, Aralaguppe SG, Singh K, Rao R, Sönnerborg A, Sarafianos SG, Neogi U. Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. J Antimicrob Chemother 2018;73:2721-8. [PMID: 30053052 DOI: 10.1093/jac/dky256] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 61 |
Zhao L, Li Z, Zhou Z, Kang X, Fang B, Ma H, Ge Q. Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic. Journal of Chromatography B 2019;1117:148-57. [DOI: 10.1016/j.jchromb.2019.04.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 62 |
Andrei G, Gillemot S, Topalis D, Snoeck R. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. J Infect Dis 2018;217:790-801. [PMID: 29186456 DOI: 10.1093/infdis/jix605] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 63 |
Puri A, Bhattaccharjee SA, Zhang W, Clark M, Singh O, Doncel GF, Banga AK. Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV. Pharmaceutics 2019;11:E173. [PMID: 30970630 DOI: 10.3390/pharmaceutics11040173] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 64 |
Bock P, Nel K, Fatti G, Sloot R, Ford N, Voget J, Gunst C, Grobbelaar N, Louis F, Floyd S, Hayes R, Ayles H, Beyers N, Fidler S; HPTN 071 (PopART) Team. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa. HIV Med 2019;20:392-403. [PMID: 30963667 DOI: 10.1111/hiv.12729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 65 |
Shen Z, Rodriguez-Garcia M, Patel MV, Bodwell J, Wira CR. Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells. Sci Rep 2019;9:1864. [PMID: 30755713 DOI: 10.1038/s41598-018-38205-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 66 |
Geant PY, Kaci M, Uttaro JP, Périgaud C, Mathé C. Synthesis and Antiviral Evaluation of 3'-Fluoro-4'-modified-5'-norcarbocyclic Nucleoside Phosphonates. ChemMedChem 2019;14:522-6. [PMID: 30637958 DOI: 10.1002/cmdc.201800804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 67 |
Phosphorus in Chemical Biology and Medicinal Chemistry. Organophosphorus Chemistry 2019. [DOI: 10.1002/9783527672240.ch10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 68 |
Brown K, Thomas D, Mckenney K, Reeder M, Simonson RB, Bicer C, Nettles RE, Crauwels H. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single‐Tablet Regimen. Clinical Pharmacology in Drug Development 2019;8:541-8. [DOI: 10.1002/cpdd.632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 69 |
Deeks ED. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs 2018;78:1013-24. [PMID: 29915897 DOI: 10.1007/s40265-018-0934-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 70 |
Crauwels HM, Baugh B, Landuyt E, Vanveggel S, Hijzen A, Opsomer M. Bioequivalence of the Once‐Daily Single‐Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability. Clinical Pharmacology in Drug Development 2019;8:480-91. [DOI: 10.1002/cpdd.628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 71 |
Marino-Merlo F, Macchi B, Armenia D, Bellocchi MC, Ceccherini-Silberstein F, Mastino A, Grelli S. Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors. Appl Microbiol Biotechnol 2018;102:9925-36. [PMID: 30269214 DOI: 10.1007/s00253-018-9390-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 72 |
Ncube S, Madikizela LM, Chimuka L, Nindi MM. Environmental fate and ecotoxicological effects of antiretrovirals: A current global status and future perspectives. Water Res 2018;145:231-47. [PMID: 30142521 DOI: 10.1016/j.watres.2018.08.017] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 73 |
Terrault NA. Hepatic Transplantation and HBV, HCV, and HIV Infections. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch38] [Reference Citation Analysis]
|
| 74 |
Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov 2018;17:559-87. [DOI: 10.1038/nrd.2018.46] [Cited by in Crossref: 311] [Cited by in F6Publishing: 325] [Article Influence: 62.2] [Reference Citation Analysis]
|
| 75 |
Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res 2018;154:66-86. [PMID: 29649496 DOI: 10.1016/j.antiviral.2018.04.004] [Cited by in Crossref: 219] [Cited by in F6Publishing: 236] [Article Influence: 43.8] [Reference Citation Analysis]
|
| 76 |
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110, GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 2018;68:672-81. [PMID: 29756595 DOI: 10.1016/j.jhep.2017.11.039] [Cited by in Crossref: 213] [Cited by in F6Publishing: 214] [Article Influence: 42.6] [Reference Citation Analysis]
|
| 77 |
Vlot MC, Grijsen ML, Prins JM, de Jongh RT, de Jonge R, den Heijer M, Heijboer AC. Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection. PLoS One 2018;13:e0193679. [PMID: 29522570 DOI: 10.1371/journal.pone.0193679] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 78 |
Chahal HS, Murray JS, Shimer M, Capella P, Presto R, Valdez ML, Lurie PG. The US Food and Drug Administration's tentative approval process and the global fight against HIV. J Int AIDS Soc 2017;20. [PMID: 29232052 DOI: 10.1002/jia2.25019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 79 |
Hummert P, Parsons TL, Ensign LM, Hoang T, Marzinke MA. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs. J Pharm Biomed Anal 2018;152:248-56. [PMID: 29433097 DOI: 10.1016/j.jpba.2018.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 80 |
Cattaneo D, Minisci D, Baldelli S, Mazzali C, Giacomelli A, Milazzo L, Meraviglia P, Resnati C, Rizzardini G, Clementi E, Galli M, Gervasoni C. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr 2018;77:86-92. [PMID: 28961682 DOI: 10.1097/QAI.0000000000001558] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 81 |
Shen Z, Rodriguez-Garcia M, Patel MV, Bodwell J, Kashuba ADM, Wira CR. Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells. Sci Rep 2017;7:17697. [PMID: 29255206 DOI: 10.1038/s41598-017-18078-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 82 |
De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochem Pharmacol 2018;153:2-11. [PMID: 29225131 DOI: 10.1016/j.bcp.2017.11.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 83 |
Lathouwers E, Wong EY, Luo D, Seyedkazemi S, De Meyer S, Brown K. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies. HIV Clin Trials 2017;18:196-204. [PMID: 29143565 DOI: 10.1080/15284336.2017.1387690] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 84 |
Ogbuagu O. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Rev Anti Infect Ther 2016;14:1113-26. [PMID: 27797606 DOI: 10.1080/14787210.2016.1255551] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 85 |
Morales MR, Sendra C, Romero-Gomez M. Hepatitis B and NAFLD: Lives Crossed. Ann Hepatol 2017;16:185-7. [PMID: 28233740 DOI: 10.5604/16652681.1231556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 86 |
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV 2018;5:e23-34. [PMID: 28993180 DOI: 10.1016/S2352-3018(17)30179-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 87 |
Smith JM, Moss JA, Srinivasan P, Butkyavichene I, Gunawardana M, Fanter R, Miller CS, Sanchez D, Yang F, Ellis S, Zhang J, Marzinke MA, Hendrix CW, Kapoor A, Baum MM. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. PLoS One 2017;12:e0185946. [PMID: 28982161 DOI: 10.1371/journal.pone.0185946] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 88 |
Mehellou Y, Rattan HS, Balzarini J. The ProTide Prodrug Technology: From the Concept to the Clinic. J Med Chem 2018;61:2211-26. [PMID: 28792763 DOI: 10.1021/acs.jmedchem.7b00734] [Cited by in Crossref: 134] [Cited by in F6Publishing: 138] [Article Influence: 22.3] [Reference Citation Analysis]
|
| 89 |
Soriano V, Barreiro P, Benitez L, Peña JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2017;26:843-51. [DOI: 10.1080/13543784.2017.1333105] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 90 |
Rodriguez-Garcia M, Patel MV, Shen Z, Bodwell J, Rossoll RM, Wira CR. Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract. Sci Rep 2017;8:45725. [PMID: 28368028 DOI: 10.1038/srep45725] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 91 |
Dobroszycki J, Lee P, Romo DL, Rosenberg MG, Wiznia A, Abadi J. Antiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges. Expert Rev Clin Pharmacol 2017;10:509-16. [PMID: 28288535 DOI: 10.1080/17512433.2017.1301205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 92 |
Wang ND, Li TS. Factors Associated with the Size of HIV DNA Reservoir. Chin Med J (Engl) 2017;130:224-30. [PMID: 28091416 DOI: 10.4103/0366-6999.198009] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
| 93 |
Cahill M, Ontiveros C. The Liver Meeting 2016. EMJ Hepatol 2017. [DOI: 10.33590/emjhepatol/10312166] [Reference Citation Analysis]
|
| 94 |
Imaz A, Podzamczer D. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Rev Anti Infect Ther 2017;15:195-209. [PMID: 28117606 DOI: 10.1080/14787210.2017.1286736] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 95 |
Iwata K, Nagata M, Watanabe S, Nishi S. Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report. BMC Pharmacol Toxicol 2016;17:52. [PMID: 27866471 DOI: 10.1186/s40360-016-0100-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 96 |
Kandil S, Balzarini J, Rat S, Brancale A, Westwell AD, McGuigan C. ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. Bioorg Med Chem Lett 2016;26:5618-23. [PMID: 27818111 DOI: 10.1016/j.bmcl.2016.10.077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 97 |
Fernando Bernal Q. FARMACOLOGÍA DE LOS ANTIRRETROVIRALES. Revista Médica Clínica Las Condes 2016;27:682-697. [DOI: 10.1016/j.rmclc.2016.09.013] [Reference Citation Analysis]
|
| 98 |
Rimawi BH, Haddad L, Badell ML, Chakraborty R. Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices. Infect Dis Obstet Gynecol 2016;2016:7594306. [PMID: 27504071 DOI: 10.1155/2016/7594306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
